FORM PTO-	1449	US Dept. of C	ommerce	ATTORNEY DOCKET NO.		SERIAL NO		
		Patent and Tra	demark Office	4333 001/3		To be ass	gred	i
			·	4012-113 9233.8DV3		09/134,803		
O. (D.	N PAC	NTAL INFORM	ATION	APPLICANT				j
SUPI	ISCI OS	SURE STATEM	ENT	Nnochiri N. Ekwuribe, et al.]
		al sheets if neces		FILING DATE GROUP 1651				
(••	Concurrently herewith		B .	05 1	
				August 14, 1998		1646-		
		DATENT	U.S.	PATENT DOCUMENTS			FILING	DATE
EXAMINER INITIAL	 	PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	IF APPRO	
	Ì							
				-				
						<u> </u>		
								1
	<u> </u>			<u> </u>				
				·				
							-	
	-							
							}	
	J	<u> </u>	FOREI	GN PATENT DOCUMENTS		:		
		DOCUMENT	PUBLICATION		CT A SE	SUBCLASS	TRANS!	LATION NO
	ļ	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	163	110
								}
	1	OTHER DOCI	MENTS (Includ	ling Author, Title, Journal-Da	te. Page N	umber, Etc.)		
25./	AA	Delgado et al.	"The Uses and P	roperties of PEG-Linked Protei	ns". <i>Critico</i>	l Review in Th	ierapeutic	Drug
Ro		Carrier System	is, 9(3, 4):249-30)4 (1992).				
							· .	
	 						<u> </u>	
	ļ						:	
				<u> </u>				
				•				
	<u> </u>	<u> </u>		Continue on Page				
EXAMINER	₹				DATEC	ONSIDERED	, .	
	-	12600	Omen			11/4/7	14	
EVALOUS.	N. T			or not citation is in conformance	with MPF	P 8 609 Draw	line throu	eh
EXAMINE	C initia	i ii citation consi	t considered In	or not citation is in comormance	t communi	cation to the a	nnlicant	G

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

Une	der the Paperwork Reduction A	ct of 1985	o persons are re		d Trademark Office; U.S. DEPARTMENT OF COMMERO information unless it contains a valid OMB control numb
·		7	6.1		Complete if Known
Substitute for form 1449B/PTO	Alia	7 8 200 E	Application Number	10/716,975	
	SUPPLEMEN	128	E O TOTA	Application Number Filing Date	November 19, 2003
	INFORMATION DIS	CVSCIII	RF	First Named Inventor	Ekwuribe, Nnochiri N., et al.
	STATEMENT BY A	PPI NEA	Ni Francis	Art Unit	1651
	INFORMATION DIS STATEMENT BY AI (use as many sheets as	necessary		Examiner Name	
Sheet	1	of	· 1	Attorney Docket Number	014811-29.8DV3

NON PATENT LITERATURE DOCUMENTS Examiner Cite								
Examiner Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T					
16	B1	SAKANE, TOSHIYASU, et al., "Carboxyl-directed Pegylation of Brain-derived Neurotrophic Factor Markedly Reduces Systemic Clearance with Minimal Loss of Biologic Activity," <i>Pharmaceutical Research</i> , Vol. 14, No. 8, pp. 1085-1091, 1997						
	:	·						
-								
Examiner Signature	<u> </u>	Restormen Date Considered 11/4/04						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO-1449 US Dept. of Commerce Patent and Trademark Office		Commerce ademark Office	ATTORNEY DOCKET NO. 9233. 8DV3		SERIAL NO. To be assigned 09/134,803		
DECORA CO	יים ואר)	SCLOSURE ST	ATEMENT	APPLICANT			
INFORMAT: 	ION DI	SCLUSUKE ST	A I EMENT	Nnochiri N. Ekwuribe			
(use several sheets if necessary)			ssary)	FILING DATE		GROUP	/
, (====================================				Concurrently hereu	11 p	1646	651
			TIC I	August 14, 1998 PATENT DOCUMENTS		1040	
EXAMINER		PATENT	U.S. 1	ATENT DOCUMENTS			FILING DATE
INITIAL		NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE
16	ÀÀ	4,585,754	29 Apr. 1986	Meisner et al.			
	AB	4,179,337	18 Dec. 1979	Davis et al.			
	AC	4,003,792	18 Jan. 1977	Mills et al.			
	AD	4,849,405	18 Jul. 1989	Есапоw			·
	AE	5,013,556	7 May 1991	Woodle et al.			i
	AF	4,963,367	16 Oct. 1990	Ecanow			
	AG	4,044,196	23 Aug. 1977	Hüper et al.			
	AH	4,717,566	5 Jan. 1988	Eckenhoff et al.			
	AI	4,698,264	6 Oct. 1987	Steinke			
	AJ	4,684,524	4 Aug. 1987	Eckenhoff et al.			
	AK	4,410,547	18 Oct. 1983	Ueno et al.			
	AL	3,256,153	14 Jun. 1966	Heimlich			
	AM	4,935,246	19 Jun. 1990	Ahrens			
	AN	4,797,288	10 Jan 1989	Sharma et al.			
	AO	4,744,976	17 May 1988	Snipes et al.			_
	AP	5,055,304	8 Oct. 1991	Makino et al.			
	AQ	5,055,300	8 Oct. 1991	Gupta			
	AR	4,772,471	20 Sep. 1988	Vanlerberghe et al.			
	AS	5,093,198	3 Mar. 1992	Speaker et al.			
	AT	4,840,799	20 Jun. 1989	Appelgren et al.	· ·		
	AU	4,622,392	11 Nov. 1986	Hong et al.			
	ΑV	5,653,987	5 Aug. 1997	Modi et al.			
	AW	5,792,834	11 Aug. 1998	Hakimi et al.			
	AX	5,595,732	21 Jan. 1997	Hakimi et al.			
Y	AY	5,539,063	23 Jul. 1996	Hakimi et al.			
				Continue on page 2			
EXAMINER		1610	omen			DATE CO	NSIDERED
EXAMINER	: Initia	Lif citation cons	idered, whether or	not citation is in conformance	with MPE	P § 609; Drav	line through

FORM PTO	FORM PTO-1449 US Dept. of Commerce Patent and Trademark O		Commerce	ATTORNEY DOCKET NO. SERIAL NO. To be assigne			 اد م	
		I alcili aliu Ti	additiank Office	4012-11 3 9233.8DV3		09/134,803		(0
TNEODMAI	רו ואראיז	ISCLOSURE ST	·ATEMENIT	APPLICANT	-			
INFORMA	ION D	ISCLUSURE 31	ATEMENT	Nnochiri N. Ekwuribe				
(1	ise seve	ral sheets if nece	ssary)	FILING DATE	TE GROUP			
				Concurrently herewi	† ~	-1646	651	
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS		G DATE OPRIATE
RO	AZ	5,559,213	24 Sep 1996	Hakimi et al.				
	BA	5,747,646	5 May 1998	Hakimi et al.				
	ВВ	5,286,637	15 Feb. 1994	Veronese et al.				
	BC	5,631,263	20 May 1997	Portoghese et al.				
	BD	5,602,099	11 Feb. 1997	Schiller				·
	BE	5,545,719	13 Aug. 1996	Shashoua et al.				
	BF	5,641,861	24 Jun. 1997	Dooley et al.	 			
	BG	5,663,295	2 Sep. 1997	Moreau et al.				····
	ВН	5,786,447	28 Jul. 1998	Schiller et al.	<u> </u>			
	BI	4,939,174	3 Jul. 1990	Shashoua				
	1	DOCUMENT	FOREIC PUBLICATION	ON PATENT DOCUMENTS			TDANC	LATION
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	BJ	WQ93/01802	4 Feb. 1993	PCT/Switzerland	-			Х
		THER DOCUM	MENTS (Includi	ing Author, Title, Journal-Da	ite Page Ni	umber Etc.)		
	BK		`	ence of Peptide Structure on Tr			lls " Phar	m Res
		1991, 8 (12): p	p. 1453-1459.	•	· ·			
	BL	Boccu, E. et al.	, "Pharmocokine mm., 1982, 14: p	tic Properties of Polyethylene (Glycol Deriv	atized Supero	xide Dism	iutase,"
	BM	Igarashi, R. et a	al., "Biologically	Active Peptides Conjugated wi	th Lecithin	for DDS" Proc	eed. Inter	n.
		Symp. Cont. Re	l. Bioactiv. Mate	er. 1990, 17: pp. 367-368.				
	BN			of Acyloyl Lysozyme and Improinistration in Rats," Proceed. In				
		1992, 19: pp. 10	04-105.					
	во	Russell-Jones, (1992; 19: pp. 1		12 Drug Delivery," Proceed. Ir	itern. Symp.	Control. Rel.	Bioactive	. Mater.,
	ВР	Baudys, M. et a	l., "Synthesis and	Characteristics of Different G	•		Insulin,"	
	BQ			 Bioactiv. Mater., 1992, 19: p ery Systems, pp. 678-679, Mar 			k NY 10	192
	عر							<u></u>
····			· · · · · · · · · · · · · · · · · · ·	Continued on page 3				
EXAMINER	4	Z 61 TO	men			DATE CON: ///4/	/	١.
				not citation is in conformance				h
citation if not	in confe	ormance and not	constaerea. Inclu	de copy of this form with next	communica	non to the app	IICANI.	

FORM PTO-	1449	US Dept. of Commerce	ATTORNEY DOCKET NO	•	SERIAL NO.
		Patent and Trademark Office	4012-113 9233.8DV	2	To be assigned
) -				<u> </u>	09/134,803
n TODA (AT)	ON DI	CCLOSIDE CTATEMENT.	APPLICANT		
INFORMATI	וט אט.	SCLOSURE STATEMENT	Nnochiri N. Ekwuribe		•
<i>(</i>		al about if = agains	FILING DATE		GROUP
(us	e sever	ral sheets if necessary)	Concurrently hereu	th.	
			August 14, 1998	11	165
	BR \	Pardridge, W.M., "CNS Drug D		Blood-Brain	
	DI (Neurochem., 1998, 70 (5): pp. 1	-	71000 DILIII .	Danier Transport, J.
-	BS	Kioll, R.A., et al., "Outwitting the		erapeutic Pur	poses: Osmotic Opening and
		Other Means," 1998 Neurosurge		•	,
	BT	Pardridge, W.M., "Blood-Brain		Peptide Dru	g Delivery to the Brain," Amer.
		Chem Soc. 1995, pp: 265-296.	-		·
	BU	Banks, W.A. et al., "Passage of	Peptides Across the Blood-Br	ain Barrier: 1	Pathophysiological
		Perspectives," Dife Sciences, 19	96, 59 (23), pp: 1923-1943.		
	BV	Fix, J.A., "Oral Controlled Relea	ise Technology for Peptides: S	Status and Fu	ture Prospects," Pharm. Res.,
		1996, 13 (12): pp: 1760-1763.			
1	BW	Terasaki, T., et al., "Oligopeptid	e Drug Delivery to the Brain,"	' Amer. Cher	n. Soc. 1995, pp. 297-316.
	BX	Bodor, N., et al., "Molecular Pac	kaging. Peptide Delivery to t	he Central N	ervous System by Sequential
1		Metabolism," Amer. Chem. Soc.	, 1995, p:317-337.		
	BY	Nestor, J., "Improved Duration of	(Action of Peptide Drugs," A	mer. Chem S	Soc. 1995, pp:449-471.
	BZ Santiago, N. et al., "Oral Immunization of Rats with Influenze Virus M Protein (M1) Microspheres,"				tein (M1) Microspheres "
	114	Proceed. Intern. Symp. Cont. Re	•		•
	CA				
1	0.1	Assoc. J. 1922, 12: pp. 141-146.			
	CB	Brange, J. et al., "Chemical Stabi		Degradation 1	During Storage of
		Pharmaceutical Preparations," Pl	narm. Res., 1992, 9 (6): pp. 7	15-726.	
	CC	Nucci, et al., "The Therapeutic V	alue of Poly(ethylene glycol)	 Modified F 	Proteins," Ac. Drug. Del. Rev.
		1991, 6: pp. 133-151.			
	CD	Brange, J. et al., "Chemical Stabi			
		Products During Storage of Pharm			
	CE	Robbins, D. C. et al., "Antibodie		isulin in Bloc	od of Insulin-Using Diabetic
	<u></u>	Patients," Diabetes, 1987, 36: pp	5. 838-841.	Turkilia ia T	ama I Diahasia Basiansa ia
·] '	CF	Maislos, M. et al., "The Source of Therapeutic Insulin," J. Clin. Inv.		Inselin in I	ype I Diabetic Fatients is
	CG	Ratner, R. E. et al., "Persistent C		lting from H	igh-Molecular Weight Insulin
	CG	Aggregates," Diabetes, 1990, 39:		ung nomen	v
·	CH	Oka, K. et al., "Enhanced Intestir	nal Absorption of a Hydrophol	oic Polymer-	Conjugated Protein Drug.
	<u> </u>	Smanes, in an Oily Formulation,"			The state of the s
	CĪ	Saffran, M. et al., "A New Appro			and Other Peptide Drugs,"
		Science, 1986, 233: pp. 1081-10	84.		
	CJ	Abuchowski, A. and F. F. Davis,	"Soluble Polymer-Enzyme Ac	iducts," pp	368-383, Enzymes as Drugs, J.
		S. Holcenberg, John Wiley, 1981			- Villa
	CK	Akiyama, M. et al., "The Synthes		D-Arabinofu	ranosylcytosine,""Chem.
		Pharm. Bull., 1978, 26(3): p. 981			M
	CL	Gish, D. T. et al., "Nucleic Acids			
		Antileukemic and Immunosuppre		., 1971, 14(1	(2): pp. 1159-1162.
		(Continue on Page 4		
EXAMINER				DATE CO	NSIDERED
	12	60 comen		111	4/04
			£		
EXAMINER:	Initial	if citation considered, whether or r	not citation is in conformance	WITH MPEP	g ouy; Draw line through
citation if not in	n conto	ormance and not considered. Inclu	de copy of this form with nex	i communica	ноп ю ше аррисапі.

FORM PTO-	FORM PTO-1449 US Dept. of Commerce Patent and Trademark Of			NEY DOCKET NO. 9233, 8013	SERIAL NO. To be assigned 09/134,803
			APPLICA		
INFORMAT	ION DI	SCLOSURE STATEMENT	Nnochiri	N. Ekwuribe	
(11)	se sever	al sheets if necessary)	EII ING	DATE	GROUP
(4.	30 30 . 4.		Concu	rently herewith	GROUP /65/ 1646-
			August 1	4, 1998-	15467
		OTHER DOCUMENTS (Includ	ing Autho	r, Title, Journal-Date, Page N	umber, Etc.)
	CM '	Baker, D. C. et al., 'Prodrugs of	9-β-D-Ar	abinofuranosyladenine. 1. Synth	nesis and Evaluation of Some 5'-
		(O-Acyl) Derivatives," J. Med.	Chem., 19	78, 21(12): pp. 1218-1221.	nid Analogs of Azidothymidine
	CN	Hostetler, K. Y. et al., "Synthesi and Other Antiviral Nucleosides	is and Anti	retroviral Activity of Phospholic	990, 265(11): pp. 6112-6117.
	СО	Hong, C. I. enal., "Nucleoside C	Conjugates.	7. Synthesis and Antitumor Ac	tivity of 1-β-D-
		Arabinofuranos vicytosine Conju	igates of E	ther Lipids," J. Med. Chem., 19	86, 29: pp. 2038-2044.
	CP Aoshima, M. et al., W-Beher			Arabinofuranosylcytosine as a Po	otential New Antitumor Agent,"
·	CO Zalipsky, S. et al., "Attachmer			o. Polyethylene Glycols " Eur. Po	olym, J., 1983, 19(12); pp. 1177-
	CQ	1183.	•	·	
	CR	Tsuzuki N et al. "Rabid Com	munication	. Adamantane as a Brain-Direc	ted Drug Carrier for Poorly
		Absorbed Drug: Antinociceptive	Effects of	f [D-Ala'] Leu-Enkephalin Deri	vatives Conjugated with the 1-
	CS	Adamantane Moiety," Biochem	acology of	Endogenous Opioid Peptides,"	Psychopharmacology: The
	Fourth Generation of Progress, 1995, pp. 5/19-529.				
	CT	CT Horvat, J., et al., "Synthesis and Biological Activity of [Leu³] Enkephalin Derivatives Containing D-			
	677	Glucose," J. Peptide Protein Res., 1988, 31, pp. 499-507. Shashoua V.E., et al., "γ-Aminobutyric Acid Esters. 1. Synthesis, Brain Uptake, and Pharmacological			
	CU	Shashoua V.E., et al., Y-Amino Studies of Aliphatic and Steroid	Esters of	v-Aminobutyric Acid," J. Med. (Chem., 1984, 27 (5), pp: 660-
		664		•	
	CV	Brewster, M., et al., "Tissue Dis	tribution o	of LY231617, an Antioxidant wi	th Neuroprotectant Activity, in
	CTU	the Rat," J. Pharm. Studies," 19	95, 84 (/), ery Excreti	on of the Model Opioid Pentide	[D-PEN ^{2.5}] Enkephalin in Rats,"
	CW	Pharm Res I 14 pp: 345-350	_	***************************************	
	CX	Bodor, N., et al., "A Strategy fo	r Deliverin	g Peptides into the Central Ner	vous System by Sequential
		Metabolism," Science, 1992, 25 Sim, L., et al., "In vitro Autorad	7 nn. 160	8-1702 ™	
	CY	Sim, L., et al., "In vitro Autorad stimulated Guanylyl 5'-[γ[³⁵ S]th	iograpny c	of Receptor-Activated of Protein	ad. Sci., USA, 1995, 92, pp.
		7242-7246			*
	CZ	Weber S.I. et al. "Whole Bod	y and Brain	n Distribution of [3H]Cyclic [D-	PEN ² , D-PEN ⁵] Enkephalin after
		Intraperitoneal, Intravenous, Or	al and Sub	cutaneous Administration, J. P.	narm. Exper., 1992, 203
	DA	pp: 1308-1316. Alyautdin, R.N., "Delivery of L	operamide	Across the Blood-Brain Barrier	with Polysorbate 80-Coated
	DA	Polybutylcyanoacrylate Nanopa	rticles." Ph	narm. Res. J., 1997, 14, pp: <u>325</u> -	-328. <u>*</u>
	DB	Chiou, G.C.Y., et al., "Systemic	Delivery	of Enkephalin Peptide through E	Eyes," Life Sciences, 1988, 43,
	BC	pp: 509-514.	with L-G	lutamic Acid for Brain Drug De	livery," Proceed. Intern. Symp.
DC Sakaeda, T., et al., "Conjugation with L-Glutamic Acid for Brain Drug Deliver Control. Rel. Bioact. Mater., 1966, 23, pp: 607-608.					
	<u> </u>		Continue	on Page 5	
EXAMINER				DATE CONSIDERED	
		SCTOMEN.		11/4/04	
EVANDED	, Initial	l if citation considered, whether or	not citatio		P § 609; Draw line through
citation if no	t in conf	formance and not considered. Inc	lude copy	of this form with next communic	cation to the applicant.

FORM PTO-	1449	US Dept. of Commerce	ATTORNEY DOCKET NO			
		Patent and Trademark Office	4012-113 9233.8DV	3 be assigned		
	*	•	APPLICANT			
INFORMATI	ON DI	SCLOSURE STATEMENT		·		
			Nnochiri N. Ekwuribe			
(use	e sever	al sheets if necessary)	FILING DATE	GROUP		
			Concurrently hereus	with 1646 1651		
	DD	Shun., W., et al., "Transmucosal	Delivery of Methionine Enke	phalin. I: Solution Stability and Kinetics of		
·		Degradation in Various Rabbit N	Aucosa Extracts," J. Pharm.Sc	i., 1993, 82 (4), pp: 373-378.		
DE Brewster, M.E., et al., "Efficac			of a 3-Substituted Versus 17-5	Substiturted Chemical Delivery System for		
Estradiol Brain Targeting," J. F						
	DF	Mosnaim, A.D., et al., "Studies of	of the in Vitro Human Plasma	Degradation of Methionine-Enkephalin,"		
Gen. Pharmac., 1988, 19 (5), pp			: 729-733.			
1	DG	Weber, S.J., et al., "Distribution	and Analgesia of ['H][D-PEN	² , D-PEN ⁵] Enkephalin and Two		
			venous Administration," J. Pha	rm. Exper. Ther., 1991, 259, pp: 1109-		
 		1112.				
1	DH			e Estrogenic Activity of a Brain-Targeting		
ļ	n .	Estradiol Chemical Delivery Sys				
	DI		iches to Drug Delivery Through the Blood-Brain Barrier," Trends in			
	<u> </u>	Biotechnology, 1994, pp: 239-24		A Donominancia Compound that		
	DJ			ne: A Dopaminergic Compound that Life Sciences, 58 (16), pp: 1347-1354.		
	DK			anyl Aminopeptidase on Leu-Enkephalin		
]	and Dynorphin-Related Peptides,	"Neuropeptides, 1989, 13, pp	o: 259-262		
	DL	Prokai-Tatrai, K., et al., "Brain-T	argeted Delivery of a Leucine	-Enkephalin Analogue by Retrometabolic		
		Design," J. Med. Chem, 1996, 39	(24).			
			1			
		·				
		Co	ontinue on Page			
EXAMINER				DATE CONSIDERED		
R6170men 14/4/04						
EXAMINER:	Initial	if citation considered, whether or	not citation is in conformance	with MPEP § 609: Draw line through		
	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					

FORM PTO-1449 US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4012-113 9233, 80 v 3		SERIAL NO Tobe ass 09/134,803				
		NTAL INFORM SURE STATEM		APPLICANT Nnochiri N. Ekwuribe, et al.			,	
_		al sheets if neces		FILING DATE		GROUP		
				August 14, 1998 Concurrent	lyhorowith	/.	657	
			U.S.	PATENT DOCUMENTS	411444	<u> </u>		
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	
No	AA	5,693,769	02 Dec 1997	Kahne et al.	536	5		
		f						
·						·		
			·	· · · · · · · · · · · · · · · · · · ·	1			
<u> </u>								
				· · · · · · · · · · · · · · · · · · ·				
· · · · · · · · · · · · · · · · · · ·								
		<u> </u>	FOREIC	N PATENT DOCUMENTS	L	<u> </u>		
		DOCUMENT	PUBLICATION	COLDEDY	GT 400	CUP CT + CC	TRANSL	
···-i		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
		MATTER DOCUMENT	ATTRICULAR IN INC.					
		THER DOCU	VIEN 15 (Includi	ing Author, Title, Journal-Da	ite, Page Ni	imber, Etc.)		
		· · · · · · · · · · · · · · · · · · ·				· 		
			· · · · · · · · · · · · · · · · · · ·					
							···- -	
				Continue on Page				
EXAMINER	· · · · · · · · · · · · · · · · · · ·	<i>t</i> 2			DATE CO	NSIDERED		
		16617	omen		/	11/4/09	<i>-</i>	j
				not citation is in conformance ude copy of this form with nex				h

FORM PTO-	FORM PTO-1449 US Dept. of Commerce	ATTORNEY DOCKET NO	IEY DOCKET NO. SERIAL NO.					
		Patent and Tra	demark Office	4012-113 9233.9 DV3 To be assigned applianted				
				APPLICANT	<u>) </u>	1 499 1 34,00 0		
DIFORMAT	וח ואו	SCLOSURE ST	ATEMENT	APPLICANT				
INFORMAT	וע אטו	SCLOSURE STA	· ·	Nnochiri N. Ekwuribe, et al.				
(us	se sever	al sheets if neces	sary)	FILING DATE		GROUP	, .	
(Concurrently herewit	h	1646	65/	
			TIE	August 14, 1998 PATENT DOCUMENTS		1040		
EXAMINER		PATENT	0.5.	PATENT DUCUMENTS	1		FILING	DATE
INITIAL		NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	IF APPRO	OPRIATE
176	AA	5,932,462	Aug. 3, 1999	Harris et al.	435	188		
165							·	
					_			
			,	,	·			
	_							
				·				
					 		•	
	ŀ						· · · · · · · · · · · · · · · · · · ·	
	 -			,				
<u></u>								
		<u> </u>	FOREIG	GN PATENT DOCUMENTS	<u> </u>		<u> </u>	
		DOCUMENT	PUBLICATION					LATION
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
			1				•	
	-							
	<u> </u>		A CONTROL (Year)	Line Andhan Tidla Jamesal F	loto Pogo N	lumber Ftc)	L	L
		OTHER DOCU	MEN 15 (Includ	ling Author, Title, Journal-L	ate, rage i	umber, Etc.)		
					`			
						`		
	 	· ·						
		1						· · · · · · · · · · · · · · · · · · ·
	L	<u></u>	<u> </u>	Continue on Page				
P3/ 43 473 (P2		<u> </u>			DATEC	ONSIDERED		
EXAMINER		P6170	an in			11/4/60		
	•				· ·	·	<u>′ </u>	
EXAMINER	l: Initia	l if citation cons	idered, whether o	r not citation is in conformance	e with MPE	P § 609; Draw cation to the ai	nne throup plicant.	gn

Substitut form 1449A/PTO	Compl te if Known			
	Application Number	To be assigned		
INFORMATION DISCLOSURE	Filing Date	Concurrently herewith		
STATEMENT BY APPLICANT	First Named Inventor	Ekwuribe		
STATEMENT BY AFFEIGANT		1657		
(use as many sheets as necessary)				
Sheet 1 of 1	Attorney Docket Number	9233.8DV3		

			U.S. PATENTS	AND PATENT PUBLICATIONS		
Examiner Initials*	Cite No.	Cite No. U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	
muais		Number	(if known)	5003	MM-DD-YYYY	
20	1.	5,061,691		Yagi et al.	10-29-1991	
116-	2.	5,428,128		Mensi-Fatthoi et al.	06-27-1995	
26	3.	6,309,633		Ekwuribe et al	10-30-2001	
-						
			-	4		
					· · · · · · · · · · · · · · · · · · ·	

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	T		
		Office	Number	Kind Code (if known)	Document	MM-DD-YYYY			
	1								
	†								

OTHER NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т			
10	4.	Anderson et al. "Structure-Activity Relationship Assessment of Conjugated Enkephalins in Centrally Mediated Analgesia" Soc. Neurosci. Abstr. 25(1):180 (1999)				

Examiner Signatur	R6 140men	Date Consider d	11/4	1/04	· ·	

^{*}EXAMINER: Initial if reference considered, whither or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.